tirzepatide coming off shortage list Eli Lilly's is the FDA's drug list: Here's what it means Big changes are happening in

They activate both GLP-1 and GIP receptors

Results: nejm.org/doi/full/10.10 #ADA2023 Retatrutide, a TRIPLE agonist (GLP1, GIP, glucagon), just released phase 2 trial results demonstrating 25% weight loss in half of people with #obesity

12 This metabolic slowdown makes it progressively harder to continue losing weight and significantly increases the risk of regaining weight once the active weight loss phase ends

To address confounding, the analysis adjusted for age, sex, obesity, smoking status, asthma, gastroesophageal reflux disease, ACE-inhibitor use, and baseline respiratory conditions using multivariable models and propensity score matching